Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pipethanate is a small molecule antimuscarinic agent with pharmacological actions similar to atropine. It acts as an antagonist at muscarinic acetylcholine receptors, leading to smooth muscle relaxation and reduction of spasticity in the gastrointestinal and urinary tracts. Pipethanate is primarily indicated for the symptomatic treatment of visceral spasms, gastrointestinal disorders (including irritable bowel syndrome), overactive bladder, biliary tract spasm, and other conditions characterized by excessive smooth muscle contraction. It can be administered orally, intramuscularly, intravenously, or rectally[1][2][3][4][5][6]. The drug is generally well-tolerated but may cause typical anticholinergic side effects such as dry mouth and blurred vision[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pipethanate.